Zacks.com on MSN

Axsome Begins Phase III Study on Solriamfetol for ADHD in Children

Axsome Therapeutics AXSM announced that it has dosed the first patient in the phase III FOCUS-2 study evaluating solriamfetol ...

Axsome Therapeutics Initiates FOCUS-2 Phase 3 Trial of Solriamfetol in Children with Attention Deficit Hyperactivity Disorder (ADHD)

The FOCUS-2 trial in children complements the recently announced FOCUS-3 trial in adolescents with ADHDNEW YORK, July 07, 2026 (GLOBE NEWSWIRE) ...

Axsome Therapeutics, Inc.: Axsome Therapeutics Initiates FOCUS-2 Phase 3 Trial of Solriamfetol in Children with Attention Deficit Hyperactivity Disorder (ADHD)

The FOCUS-2 trial in children complements the recently announced FOCUS-3 trial in adolescents with ADHD NEW YORK, July 07, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharm ...

A teenager just turned eye scans into an AI test for autism and ADHD

A school project prompted 17-year-old Edward Kang to develop an AI tool that may lead to earlier diagnoses of the disorders.
eLife

Theta beta ratio in attention deficit hyperactivity disorder using a multiverse analysis

Individual alpha peak frequency and aperiodic neural activity shape theta-beta ratio estimates, limiting their value as an ADHD biomarker.